• J. Am. Coll. Cardiol. · Jul 2014

    Randomized Controlled Trial Multicenter Study

    Comprehensive analysis of mortality among patients undergoing TAVR: results of the PARTNER trial.

    • Lars G Svensson, Eugene H Blackstone, Jeevanantham Rajeswaran, Nicholas Brozzi, Martin B Leon, Craig R Smith, Michael Mack, D Craig Miller, Jeffrey W Moses, E Murat Tuzcu, John G Webb, Samir Kapadia, Gregory P Fontana, Raj R Makkar, David L Brown, Peter C Block, Robert A Guyton, Vinod H Thourani, Augusto D Pichard, Joseph E Bavaria, Howard C Herrmann, Mathew R Williams, Vasilis Babaliaros, Philippe Généreux, Jodi J Akin, and PARTNER Trial Investigators.
    • Cleveland Clinic, Cleveland, Ohio; PARTNER Publication Office, New York, New York, and Cleveland, Ohio. Electronic address: svenssl@ccf.org.
    • J. Am. Coll. Cardiol. 2014 Jul 15;64(2):158-68.

    BackgroundPatients with severe aortic stenosis (AS) who were deemed too high risk or inoperable for conventional aortic valve replacement (AVR) in the PARTNER (Placement of Aortic Transcatheter Valves) trial were randomized to transcatheter aortic valve replacement (TAVR) versus AVR (PARTNER-A arm) or standard therapy (PARTNER-B arm).ObjectivesThis study compared when and how deaths occurred after TAVR versus surgical AVR or standard therapy.MethodsThe PARTNER-A arm included 244 transfemoral (TF) and 104 transapical (TA) TAVR patients, and 351 AVR patients; the PARTNER-B arm included 179 TF-TAVR patients and 179 standard therapy patients. Deaths were categorized as cardiovascular, noncardiovascular, or uncategorizable, and were characterized by multiphase hazard modelling.ResultsIn the PARTNER-A arm, the risk of death peaked after randomization in the TA-TAVR and AVR groups, falling to low levels commensurate with the U.S. population within 3 months. Early risk was less in TF-TAVR patients, resulting in initial superior survival; between 12 and 18 months, risk increased, such that within 2 years, TF-TAVR and AVR patients had similar survival rates. Cardiovascular, noncardiovascular, and uncategorizable deaths for TF-TAVR were 37%, 43%, and 20%, respectively, versus 22%, 41%, and 37%, respectively, for TA-TAVR and 33%, 43%, and 24%, respectively, for AVR. In the PARTNER-B arm, risk with standard therapy was 60% per year; TF-TAVR reduced risk to 20% per year, resulting in 0.5 years of life added within 2.5 years.ConclusionsIn inoperable AS patients, TAVR substantially reduced the risk of cardiovascular death. In high-risk patients, TA-TAVR and AVR were associated with elevated peri-procedural risk more than with TF-TAVR, although cardiovascular death was higher after TF-TAVR. Therefore, TF-TAVR should be considered the standard of care for severely symptomatic inoperable patients or those at high risk of noncardiovascular mortality after conventional surgery. (THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial; NCT00530894).Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

      Pubmed     Free full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…